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BACKGROUND
We previously reported that olaparib led to significantly longer imaging-based pro-
gression-free survival than the physician’s choice of enzalutamide or abiraterone 
among men with metastatic castration-resistant prostate cancer who had qualify-
ing alterations in homologous recombination repair genes and whose disease had 
progressed during previous treatment with a next-generation hormonal agent. The 
results of the final analysis of overall survival have not yet been reported.
METHODS
In an open-label, phase 3 trial, we randomly assigned patients in a 2:1 ratio to re-
ceive olaparib (256 patients) or the physician’s choice of enzalutamide or abiraterone 
plus prednisone as the control therapy (131 patients). Cohort A included 245 pa-
tients with at least one alteration in BRCA1, BRCA2, or ATM, and cohort B included 
142 patients with at least one alteration in any of the other 12 prespecified genes. 
Crossover to olaparib was allowed after imaging-based disease progression for pa-
tients who met certain criteria. Overall survival in cohort A, a key secondary end 
point, was analyzed with the use of an alpha-controlled, stratified log-rank test at 
a data maturity of approximately 60%. The primary and other key secondary end 
points were reported previously.
RESULTS
The median duration of overall survival in cohort A was 19.1 months with olaparib 
and 14.7 months with control therapy (hazard ratio for death, 0.69; 95% confidence 
interval [CI], 0.50 to 0.97; P = 0.02). In cohort B, the median duration of overall sur-
vival was 14.1 months with olaparib and 11.5 months with control therapy. In the 
overall population (cohorts A and B), the corresponding durations were 17.3 months 
and 14.0 months. Overall, 86 of 131 patients (66%) in the control group crossed over 
to receive olaparib (56 of 83 patients [67%] in cohort A). A sensitivity analysis that 
adjusted for crossover to olaparib showed hazard ratios for death of 0.42 (95% CI, 
0.19 to 0.91) in cohort A, 0.83 (95% CI, 0.11 to 5.98) in cohort B, and 0.55 (95% CI, 
0.29 to 1.06) in the overall population.
CONCLUSIONS
Among men with metastatic castration-resistant prostate cancer who had tumors 
with at least one alteration in BRCA1, BRCA2, or ATM and whose disease had progressed 
during previous treatment with a next-generation hormonal agent, those who were 
initially assigned to receive olaparib had a significantly longer duration of overall 
survival than those who were assigned to receive enzalutamide or abiraterone plus 
prednisone as the control therapy, despite substantial crossover from control therapy 
to olaparib. (Funded by AstraZeneca and Merck Sharp & Dohme; PROfound 
ClinicalTrials.gov number, NCT02987543.)
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Metastatic castration-resistant prostate cancer remains lethal.1 Men with deleterious alterations in genes 
involved in homologous recombination repair, 
such as BRCA1 and BRCA2, have more aggressive 
disease and higher mortality than those with 
proficient homologous recombination repair.2-12 
The goal of treatment is to prolong survival while 
maintaining or improving quality of life.13 Tumors 
with gene alterations that affect homologous re-
combination repair are sensitive to poly(adenosine 
diphosphate–ribose) polymerase (PARP) inhibi-
tors.14-21 Findings from a phase 2 trial of the PARP 
inhibitor olaparib in patients with metastatic 
castration-resistant prostate cancer and homolo-
gous recombination deficiency were confirmed 
in the PROfound trial, a phase 3, randomized 
trial.17,21,22
The PROfound trial enrolled patients with 
metastatic castration-resistant prostate cancer who 
had alterations in at least 1 of 15 prespecified 
genes with a direct or indirect role in homologous 
recombination repair and whose disease had pro-
gressed during previous treatment with a next-
generation hormonal agent. The overall popula-
tion comprised patients who had at least one 
alteration in BRCA1, BRCA2, or ATM (cohort A) 
and patients with at least one alteration in any 
of the other 12 prespecified genes (cohort B). In 
cohort A, the patients who received olaparib had 
a significantly longer duration of imaging-based 
progression-free survival than those who re-
ceived the physician’s choice of enzalutamide or 
abiraterone plus prednisone (control) (hazard 
ratio for progression or death, 0.34; 95% confi-
dence interval [CI], 0.25 to 0.47; P<0.001).22 Ben-
efits with olaparib were also shown with respect 
to the key secondary end points of confirmed 
objective response rate, defined as the percent-
age of patients who had an imaging-based com-
plete response or partial response (higher with 
olaparib than with control), and time to pain 
progression in cohort A (longer with olaparib 
than control).22 An exploratory analysis in cohort 
B revealed a hazard ratio (olaparib vs. control) 
for imaging-based progression or death of 0.88 
(95% CI, 0.58 to 1.36) (Fig. S1 in the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org).22 An interim analysis of 
overall survival in cohort A at a data maturity of 
38% showed a median duration of overall sur-
vival of 18.5 months in the olaparib group, as 
compared with 15.1 months in the control group, 
despite substantial crossover from control ther-
apy to olaparib.22 Here, we report the results of 
the final prespecified analyses of overall survival 
in cohort A, a key secondary end point.
Me thods
Trial Design and Patients
A detailed account of the methods, including all 
eligibility criteria, has been published previous-
ly.22 Briefly, the trial enrolled men with meta-
static castration-resistant prostate cancer whose 
disease had progressed during previous treatment 
with enzalutamide, abiraterone, or both. Previous 
taxane chemotherapy was allowed. All the pa-
tients provided written informed consent.
An investigational clinical trial assay, based 
on the FoundationOne CDx next-generation se-
quencing test that was developed in partnership 
with Foundation Medicine, was used to prospec-
tively identify patients with a qualifying deleteri-
ous or suspected deleterious alteration in at least 
1 of the following 15 prespecified genes, which 
were selected on the basis of their direct or indi-
rect role in homologous recombination repair: 
BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, 
CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, 
RAD51D, and RAD54L (Fig. S2). Confirmation of 
homologous recombination deficiency by means 
of a genomic instability test was not a require-
ment for patient eligibility.
Patients were randomly assigned in a 2:1 ratio 
to receive olaparib (300 mg twice daily) or the 
physician’s choice of enzalutamide (160 mg once 
daily) or abiraterone (1000 mg once daily) plus 
prednisone (5 mg twice daily) (control). Subse-
quent therapies were administered at the discre-
tion of the investigators. Patients who were as-
signed to the control group were allowed to cross 
over to receive olaparib as a first subsequent anti-
cancer therapy if they had disease progression 
(verified by blinded, independent central review 
if it occurred before the primary analysis data 
cutoff date of June 4, 2019, or by site investigator 
review if it occurred thereafter), had not received 
other subsequent anticancer therapy, had no 
unresolved toxic effects from previous therapy 
that were uncontrolled or greater than grade 1 at 
the time of initiating treatment with olaparib, 
and had agreed to continue attending the sched-
uled trial visits.
The New England Journal of Medicine 
Downloaded from nejm.org at Radboud University Nijmegen on October 8, 2021. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
n engl j med 383;24 nejm.org December 10, 2020 2347
Survival with Olaparib in Prostate Cancer
End Points
Primary and key secondary end points were re-
ported previously.22 Overall survival (defined as 
the time from randomization to death from any 
cause regardless of whether the patient withdrew 
from the assigned therapy or received another 
anticancer therapy) in cohort A was a key alpha-
controlled secondary end point. A prespecified 
sensitivity analysis was performed to explore the 
effect of crossover from control therapy to olapa-
rib on overall survival. Prespecified subgroup 
analyses were also performed to assess the con-
sistency of the treatment effect across potential 
prognostic factors. Central assessment of tumor 
response was stopped when imaging-based dis-
ease progression occurred during the assigned 
treatment. Imaging-based disease progression 
was defined as soft-tissue disease progression 
according to the Response Evaluation Criteria in 
Solid Tumors, version 1.1, or bone lesion pro-
gression according to the criteria of the Prostate 
Cancer Clinical Trials Working Group 3.
The time from randomization to a second 
progression (after a first event) or death was a 
secondary end point and was based on investiga-
tor assessment of either imaging-based or clinical 
disease progression or death; assessment was 
commenced after patients had begun a subsequent 
anticancer treatment. Adverse events were moni-
tored throughout the trial and were graded ac-
cording to the Common Terminology Criteria for 
Adverse Events, version 4.03.23
Trial Oversight
The trial was performed in accordance with the 
principles of the Declaration of Helsinki, the In-
ternational Conference on Harmonisation Good 
Clinical Practice guidelines, and the AstraZene-
ca and Merck policies on bioethics. Representa-
tives of AstraZeneca designed the trial in col-
laboration with the trial steering committee and 
were responsible for overseeing the collection, 
analysis, and interpretation of the data. All the 
authors had full access to the data. Merck pro-
vided input regarding data interpretation. The 
manuscript was written with medical writing 
assistance funded by AstraZeneca and Merck 
Sharp & Dohme, with critical review and input 
by the authors. The authors vouch for the accu-
racy and completeness of the data and for the 
fidelity of the trial to the protocol, available at 
NEJM.org.
Statistical Analysis
A hierarchical multiple-testing procedure was 
used to control for the trial-wide type I error rate 
in the analyses of the primary end point of im-
aging-based progression-free survival (assessed 
by blinded independent central review), the key 
secondary end point of overall survival in cohort 
A, and the other key secondary end points, as 
reported previously (Fig. S3).22 The final analysis 
of overall survival was performed on an inten-
tion-to-treat basis and was planned when ap-
proximately 60% of the patients in cohort A had 
died. According to the multiple testing procedure, 
overall survival in cohort A was analyzed with 
the use of a stratified log-rank test, with the two-
sided alpha level of 5% split at the interim analy-
sis (0.01) and final analysis (0.047) on the basis 
of an O’Brien–Fleming spending function.24 The 
prespecified sensitivity analysis of overall survival 
that adjusted for the effect of crossover of patients 
from control therapy to olaparib was performed 
with the use of rank-preserving structural failure 
time models.25,26 Because the statistical analysis 
plan (available with the protocol) did not include 
a provision for correcting for multiplicity when 
conducting tests for other secondary or explor-
atory end points, the results are reported as point 
estimates with 95% confidence intervals, and the 
widths of the confidence intervals should not be 
used to infer treatment effects.
The safety population comprised all patients 
who had undergone randomization and received 
at least one dose of a trial drug. Safety data were 
also collected from all the patients in the control 
group who had crossed over to receive olaparib 
in accordance with the protocol and received at 
least one dose of olaparib. Safety data were ana-
lyzed with the use of descriptive statistics. Ad-
ditional details of the statistical methods are 
provided in the Supplementary Appendix and in 
the statistical analysis plan in the protocol. The 
data cutoff date for the final analysis of overall 
survival was March 20, 2020.
R esult s
Patients and Treatment
The demographic and clinical characteristics of 
the patients at baseline are provided in Table S1.22 
At the time of the final analysis, 68 patients in the 
olaparib group and 33 in the control group re-
mained in the trial; of these patients, 14 and 2, 
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respectively, were receiving olaparib or control 
therapy as assigned (Fig. S4). The crossover-adjust-
ed analysis included 86 of 131 patients (66%) in 
the control group who had crossed over to re-
ceive olaparib; this subgroup included 83 of 99 
patients (84%) who had disease progression and 
chose to cross over in accordance with the pro-
tocol and 3 additional patients who did not 
meet the crossover eligibility criteria and re-
ceived olaparib outside of the trial.
Overall Survival
Cohort A
At the time of the final analysis of overall sur-
vival, 148 of 245 patients (60%) in cohort A had 
died, so the prespecified criteria for significance of 
the overall survival end point were met. The me-
dian duration of overall survival was 19.1 months 
with olaparib and 14.7 months with control thera-
py (hazard ratio for death, 0.69; 95% CI, 0.50 to 
0.97; P = 0.02) (Fig. 1A). A sensitivity analysis that 
adjusted for crossover from control therapy to 
olaparib showed a hazard ratio of 0.42 (95% CI, 
0.19 to 0.91) (Fig. 1B).
Cohort B
At the time of the final analysis of overall sur-
vival, 100 of 142 patients (70%) in cohort B had 
died. The median duration of overall survival 
was 14.1 months with olaparib and 11.5 months 
with control therapy (hazard ratio for death, 0.96; 
95% CI, 0.63 to 1.49) (Fig. 2A). After adjustment 
for crossover from control therapy to olaparib, 
the hazard ratio was 0.83 (95% CI, 0.11 to 5.98) 
(Fig. 2B). The role of PPP2R2A as a homologous 
recombination repair gene could not be validat-
ed on the basis of preclinical data (Fig. S9), and 
no benefit of olaparib over control therapy with 
respect to overall survival was noted among pa-
tients who had alterations in PPP2R2A (hazard 
ratio for death, 5.11; 95% CI, 1.10 to 35.73) (Fig. 
S5B). In a post hoc exploratory sensitivity analy-
sis that excluded these patients from cohort B, 
the hazard ratio for death was 0.79 (95% CI, 0.51 
to 1.25) for the comparison between olaparib 
and control therapy, and the median duration of 
overall survival was 14.2 months with olaparib 
and 10.8 months with control therapy (Fig. S10A).
Overall Population
After the death of 248 of 387 patients (64%) in the 
overall population (cohorts A and B), the median 
duration of overall survival was 17.3 months with 
olaparib and 14.0 months with control therapy 
(hazard ratio for death, 0.79; 95% CI, 0.61 to 1.03) 
(Fig. 3A). After adjustment for crossover from 
control therapy to olaparib, the hazard ratio was 
0.55 (95% CI, 0.29 to 1.06) (Fig. 3B). In a sensitiv-
ity analysis that excluded patients who had altera-
tions in PPP2R2A, the hazard ratio was 0.76 (95% 
CI, 0.58 to 1.00), and the median duration of 
overall survival was 17.4 months with olaparib and 
13.6 months with control therapy (Fig. S10B).
Prespecified Subgroup Analyses
In cohort A, prespecified subgroup analyses ac-
cording to demographic and clinical characteris-
tics at baseline, including previous use of taxane 
(yes vs. no), are shown in Figure 4. When these 
same prespecified analyses were performed in the 
overall population, the benefit of olaparib over 
control therapy with respect to overall survival 
was less clear than in cohort A (Fig. S5A).
Exploratory Gene-Level Analyses
Exploratory gene-level analyses showed hazard 
ratios for death (olaparib vs. control) of 0.42 
(95% CI, 0.12 to 1.53) among patients with an 
alteration in only BRCA1 and 0.59 (95% CI, 0.37 
to 0.95) among patients with an alteration only 
in BRCA2; exploratory gene-level analyses of other 
genes were also performed when there were suf-
ficient numbers of patients and events (Figs. S5B 
and S6). The hazard ratio for death among pa-
tients with an alteration in any non-BRCA gene 
was 0.95 (95% CI, 0.68 to 1.34) in the intention-
to-treat population; after adjustment for cross-
over, the hazard ratio was 0.82 (95% CI, 0.25 to 
2.68) (Fig. S7A). Findings from exploratory anal-
yses that included patients with an alteration in 
only ATM or CDK12 are shown in Figure S7B and 
S7C. Post hoc subgroup analyses according to 
previous use of taxane in patients with an altera-
tion in only BRCA1 or BRCA2, ATM, or CDK12 are 
shown in Figure S8.
Time to Second Progression or Death
The median time until a second progression or 
death in cohort A, as assessed by the investigators, 
was 15.5 months with olaparib and 10.6 months 
with control therapy (hazard ratio for second 
progression or death, 0.64; 95% CI, 0.45 to 0.93) 
(Fig. S11A). The corresponding values in cohort 
B were 9.9 months and 7.9 months (hazard ratio, 
0.77; 95% CI, 0.50 to 1.21) (Fig. S11B); in the 
overall population, the values were 13.4 months 
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Figure 1. Kaplan–Meier Estimates of Overall Survival and Corresponding Crossover-Adjusted Sensitivity Analyses  
in Cohort A.
Panel A shows overall survival among the patients in the intention-to-treat population who had at least one altera-
tion in BRCA1, BRCA2, or ATM (cohort A). Panel B shows overall survival in cohort A, as adjusted with the use of a 
rank-preserving structural failure time model (with a recensoring approach to avoid possible informative censoring 
bias) to show the effect of crossover of patients from control therapy to olaparib as a subsequent anticancer thera-
py. For the patients who had censored data, the median duration of follow-up was 21.9 months among those in the 
olaparib group and 21.0 months among those in the control group. The alpha spent at the final analysis of overall 
survival was 0.047. Among the 83 patients in cohort A who were assigned to the control group, 56 (67%) crossed 
over to receive olaparib.
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and 9.7 months (hazard ratio, 0.68; 95% CI, 0.51 
to 0.90) (Fig. S11C).
Subsequent Anticancer Therapies
In cohort A, 79 of 162 patients (49%) in the 
olaparib group and 64 of 83 patients (77%) in 
the control group received a subsequent antican-
cer therapy; the corresponding values in the 
overall population were 129 of 256 patients 
(50%) and 96 of 131 patients (73%) (Table S2). 
Among the 64 patients in the control group in 
cohort A who received a subsequent anticancer 
therapy, 56 (67%) received olaparib and 8 (10%) 
received a different anticancer therapy, with no 
use of olaparib. The most common subsequent 
therapies other than olaparib were docetaxel 
Olaparib
Control
Patients who crossed over, 63% (30/48)
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(11 patients [13%]) and cabazitaxel (10 patients 
[12%]); these patients included those who re-
ceived docetaxel or cabazitaxel as a first subse-
quent therapy and those who had crossed over to 
receive olaparib as a first subsequent therapy and 
also received docetaxel or cabazitaxel as further 
therapy. A subsequent anticancer therapy was 
not initiated in 19 of the 83 patients (23%) in the 
control group. The most common subsequent 
anticancer therapies among the 162 patients in 
the olaparib group in cohort A were docetaxel 
(26 patients [16%]), cabazitaxel (19 patients [12%]), 
and enzalutamide (16 patients [10%]). The find-
ings were similar in the overall population.
Safety
The median duration of treatment was 7.6 months 
(range, 0.03 to 28.9) in the olaparib group and 
3.9 months (range, 0.6 to 29.1) in the control 
group; the median duration of treatment with 
olaparib among the 83 patients in the control 
group who crossed over to receive olaparib in 
accordance with the protocol was 4.8 months 
(range, 0.2 to 28.9). No new safety signals were 
observed after the longer follow-up, as compared 
with the follow-up period in the primary analy-
sis (Table S3). The most common adverse events 
among the patients in the olaparib group and 
those who crossed over to receive olaparib were 
anemia, nausea, and fatigue or asthenia; among 
those in the control group, the most common 
adverse events were anemia, fatigue or asthenia, 
and decreased appetite (Table 1 and Table S5). 
Adverse events that were suspected by the site 
investigators to be causally related to olaparib 
were most frequently anemia (occurring in 39% 
of the patients), nausea (in 36%), and fatigue or 
asthenia (in 32%); olaparib was discontinued 
because of anemia in 7% of the patients and 
because of neutropenia, thrombocytopenia, nau-
sea, vomiting, or fatigue or asthenia in 1% of the 
patients for each (Table S8). The most common 
adverse events that were suspected to be causally 
related to control therapy were fatigue or asthe-
nia (occurring in 21% of the patients), nausea (in 
11%), and decreased appetite (in 7%). Fatigue or 
asthenia that was considered to be causally re-
lated to control therapy led to treatment discon-
tinuation in 2% of the patients.
No additional cases of a second new primary 
malignant tumor, pneumonitis, or myelodysplas-
tic syndrome or acute myeloid leukemia were 
noted during the 30-day safety follow-up period. 
One case of fatal acute myeloid leukemia was re-
ported in a 75-year-old White male patient who 
had a germline BRCA2 alteration that was diag-
nosed 54 days after the discontinuation of olapa-
rib (duration of olaparib exposure, 15.7 months).
Adverse events led to death in 10 of 256 pa-
tients (4%) in the olaparib group, in 6 of 130 pa-
tients (5%) in the control group, as well as in 3 of 
83 patients (4%) who crossed over from control 
therapy to receive olaparib in accordance with 
the protocol (Table S9). Two deaths were consid-
ered to be causally related to a trial treatment: 
one from pneumonia and neutropenia in the 
olaparib group and one from pleural effusion in 
the control group.
Discussion
In this trial involving men with metastatic cas-
tration-resistant prostate cancer whose disease 
had progressed during previous treatment with 
a next-generation hormonal agent, overall surviv-
al in cohort A (those who had an alteration in 
BRCA1, BRCA2, or ATM) was a prespecified key 
alpha-controlled secondary end point. In cohort A, 
the patients who received olaparib had a signifi-
cantly longer duration of overall survival than 
those who received a control therapy (enzalutamide 
or abiraterone plus prednisone) (19.1 months vs. 
14.7 months; hazard ratio for death, 0.69; 95% CI, 
0.50 to 0.97; P = 0.02). The risk of death was 31% 
Figure 2 (facing page). Kaplan–Meier Estimates  
of Overall Survival and Corresponding Crossover- 
Adjusted Sensitivity Analyses in Cohort B.
Panel A shows overall survival among the patients in 
the intention-to-treat population who had at least one 
alteration in one of the prespecified genes with a di-
rect or indirect role in homologous recombination re-
pair other than BRCA1, BRCA2, or ATM (cohort B). The 
12 other prespecified genes included BARD1, BRIP1, 
CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, 
RAD51B, RAD51C, RAD51D, and RAD54L. Panel B shows 
overall survival in cohort B, as adjusted with the use of 
a rank-preserving structural failure time model (with a 
recensoring approach to avoid possible informative cen-
soring bias) to show the effect of crossover of patients 
from control therapy to olaparib as a subsequent anti-
cancer therapy. For the patients who had data that were 
censored, the median duration of follow-up was 18.7 
months among those in the olaparib group and 18.3 
months in the control group. Among the 48 patients 
in cohort B who were assigned to the control group, 
30 (63%) crossed over to receive olaparib. The analyses 
performed in cohort B were not alpha-controlled, and 
definitive treatment effects should not be inferred.
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lower with olaparib than with control therapy, 
despite substantial crossover from control ther-
apy to olaparib. The median duration of treatment 
with olaparib among the patients who crossed 
over was 4.8 months, and the median duration 
of treatment with control therapy was 3.9 months. 
These findings support the previously reported 
result of a significantly longer duration of imag-
ing-based progression-free survival with olaparib 
than with control therapy in the same patient 
population.22
Phase 2 trials have shown that antitumor ac-
tivity with PARP inhibition in patients with meta-
static castration-resistant prostate cancer varies 
Olaparib
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Patients who crossed over, 66% (86/131)
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according to the DNA-repair gene alterations they 
express, with consistently higher response rates 
among those with BRCA2 alterations.14,21 Patients 
in cohort A, and particularly the high percentage 
of patients who had tumors with a BRCA1 or 
BRCA2 alteration,22 appeared to derive the great-
est benefit from olaparib with respect to overall 
survival. The trial was not designed to test the 
benefit of therapy with respect to overall survival 
at the individual gene level. However, a clinical 
benefit was not observed for olaparib in the 
population of patients who had other homolo-
gous recombination repair gene alterations. These 
data, including the results of sensitivity analyses 
that excluded patients with PPP2R2A alterations, 
and the recent regulatory approval of olaparib for 
metastatic castration-resistant prostate cancer in 
which this gene alteration was excluded27 high-
light that additional studies are now required to 
further delineate genomic indicators of response 
to PARP inhibition.
Post hoc, gene-level subgroup analyses accord-
ing to previous use of taxane in patients who had 
an alteration in only BRCA1, BRCA2, ATM, or 
CDK12 provide some insight into the potential ef-
fect of previous therapy on the treatment effect of 
olaparib. The effect of previous use of taxane on 
overall survival was observed predominantly in 
the analysis that included patients with only ATM 
loss, in which olaparib seemed to show a benefit 
over control therapy in those who had previously 
received taxane therapy, as compared with those 
who had not. However, this trial was not powered 
to detect a treatment effect across any subgroup; 
moreover, the patient number and number of 
events in some subgroups were limited, and the 
analyses were not adjusted for confounding fac-
tors (e.g., baseline prognostic factors, differences 
in disease burden and treatment history at base-
line, and crossover from control therapy to olapa-
rib after disease progression). Therefore, the 
results of these subgroup analyses should be 
interpreted with caution.
The safety profile of olaparib in this final 
analysis was consistent with that in the primary 
analysis,22 with no cumulative toxic effects ob-
served during the extended exposure period. 
During the 30-day safety follow-up period, the 
number of cases of a second new primary ma-
lignant tumor or pneumonitis did not increase 
over those reported in the primary analysis; how-
ever, one case of acute myeloid leukemia was re-
ported during follow-up for overall survival.
These data on overall survival are supported 
by the observation that the interval between a 
first progression and a second progression or 
death was longer with olaparib than with con-
trol therapy, despite substantial crossover from 
control therapy to olaparib. However, this was an 
investigator-assessed end point and thereby po-
tentially subject to reporting bias. Patients who 
crossed over from control therapy to receive olapa-
rib had a shorter median duration of olaparib 
exposure (4.8 months) than those who were ran-
domly assigned to receive olaparib (7.6 months). 
Thus, earlier treatment with olaparib may have an 
advantage over its use later in the disease course.
When the PROfound trial was designed, data 
from phase 3 randomized trials that would vali-
date the efficacy of switching from one next-
generation hormonal therapy directed at andro-
gen signaling to another were lacking, although 
such sequential use has been commonly applied 
in clinical practice. Small clinical studies that 
assessed sequential next-generation hormonal 
therapy had shown some antitumor activity, and 
because patients with disease progression had 
restricted options for systemic treatment,28,29 this 
approach was incorporated into clinical guide-
lines and adopted as a standard of care.30 With 
the caveat that cross-trial comparisons should be 
considered with caution, we note that recently 
reported data from the CARD trial have shown 
Figure 3 (facing page). Kaplan–Meier Estimates  
of Overall Survival and Corresponding Crossover- 
Adjusted Sensitivity Analyses in the Overall Population.
Panel A shows overall survival among the patients in 
the intention-to-treat population who had at least one 
alteration in any of the 15 prespecified genes with a 
direct or indirect role in homologous recombination 
repair (overall population). Panel B shows overall sur-
vival in the overall population, as adjusted with the 
use of a rank-preserving structural failure time model 
(with a recensoring approach to avoid possible infor-
mative censoring bias) to show the effect of crossover 
of patients from control therapy to olaparib as a sub-
sequent anticancer therapy. For the patients who had 
data that were censored, the median duration of fol-
low-up was 20.7 months among those in the olaparib 
group and 20.5 months among those in the control 
group. Among the 131 patients in the overall popula-
tion who were assigned to the control group, 86 (66%) 
crossed over to receive olaparib (83 crossed over in 
accordance with the protocol and 3 received olaparib 
outside the trial). The analyses performed in the over-
all population were not alpha-controlled, and defini-
tive treatment effects should not be inferred.
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that the efficacy of cabazitaxel was superior to 
that of a second androgen-signaling–directed, 
next-generation hormonal agent in patients (not 
selected on the basis of biomarkers) who had 
previously been treated with docetaxel and whose 
disease had progressed during 12 months of 
previous treatment with a next-generation hor-
monal agent.31 However, data to guide treatment 
sequencing for patients with metastatic castra-
tion-resistant prostate cancer and homologous 
recombination deficiency remain sparse outside 
of that trial. In addition, cabazitaxel was not 
considered to be an appropriate choice for the 
control treatment in the PROfound trial, because 
it is only approved for use after docetaxel,32 and 
patients were included in our trial regardless of 
previous receipt of chemotherapy.
In this analysis of overall survival among pa-
tients with metastatic castration-resistant prostate 
cancer who had tumors with at least one alteration 
in BRCA1, BRCA2, or ATM and whose disease had 
progressed during previous treatment with a next-
Figure 4. Subgroup Analyses of Overall Survival in Cohort A, According to Baseline Demographic and Clinical 
Characteristics of the Patients.
Subgroups in which fewer than five patients had died were not included in the analysis. The sizes of the circles are 
proportional to the number of events. The dashed vertical line indicates the point of no effect (hazard ratio, 1.00). 
The solid vertical line indicating the point estimate in all the patients who were included in the analysis has been 
added. Subgroup analyses were not alpha-controlled, and definitive treatment effects should not be inferred. East-
ern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with higher numbers re-
flecting greater disability). Data on race were gathered by the site investigators and reported on the electronic case-
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generation hormonal agent, olaparib led to signifi-
cantly longer overall survival than enzalutamide or 
abiraterone plus prednisone. This improvement 
was noted despite substantial crossover from con-
trol therapy to olaparib. Previously defined ad-
verse effects of olaparib (e.g., anemia, nausea, 
and fatigue or asthenia) were observed in this trial.
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Table 1. Adverse Events in the Overall Population (Cohorts A and B) and in the Subgroup of Patients Who Crossed Over from Control 








All Grades Grade ≥3 All Grades Grade ≥3 All Grades Grade ≥3
number of patients with event (percent)
Any adverse event 246 (96) 133 (52) 115 (88) 52 (40) 77 (93) 49 (59)
Anemia§ 127 (50) 58 (23) 20 (15) 7 (5) 43 (52) 24 (29)
Nausea 110 (43) 4 (2) 27 (21) 0 24 (29) 2 (2)
Fatigue or asthenia¶ 107 (42) 8 (3) 43 (33) 7 (5) 21 (25) 8 (10)
Decreased appetite 80 (31) 4 (2) 24 (18) 1 (<1) 15 (18) 2 (2)
Diarrhea 55 (21) 2 (<1) 9 (7) 0 12 (14) 0
Vomiting 51 (20) 6 (2) 17 (13) 1 (<1) 16 (19) 1 (1)
Constipation 49 (19) 0 19 (15) 0 12 (14) 0
Back pain 36 (14) 2 (<1) 18 (14) 2 (2) 8 (10) 0
Peripheral edema 34 (13) 0 10 (8) 0 3 (4) 0
Cough 29 (11) 0 3 (2) 0 4 (5) 0
Dyspnea 27 (11) 6 (2) 5 (4) 0 4 (5) 1 (1)
Arthralgia 26 (10) 1 (<1) 14 (11) 0 4 (5) 0
Urinary tract infection 21 (8) 5 (2) 15 (12) 5 (4) 12 (14) 3 (4)
Any serious adverse event‖ 94 (37) NA 39 (30) NA 27 (33) NA
Interruption of treatment because of 
adverse event
119 (46) NA 25 (19) NA 44 (53) NA
Dose reduction because of adverse event 60 (23) NA 7 (5) NA 27 (33) NA
Discontinuation of treatment due to  
adverse event
51 (20) NA 11 (8) NA 11 (13) NA
Death due to adverse event 10 (4) NA 6 (5) NA 3 (4) NA
*  Adverse events, regardless of the investigators’ assessment of causality, are reported for those that occurred in at least 10% of the patients 
in either treatment group. Patients who reported multiple adverse events were counted once for each type of adverse event, even if they re-
ported multiple occurrences of a particular adverse event. The safety analysis set included all the patients who had been randomly assigned 
to receive olaparib or the physician’s choice of enzalutamide or abiraterone plus prednisone (control) and received at least one dose of a 
trial drug. Adverse events were graded according to the Common Terminology Criteria for Adverse Events, version 4.03.23 NA denotes not 
applicable.
†  One patient in the control group did not receive treatment.
‡  Patients in the control group were allowed to cross over to receive olaparib after disease progression in accordance with the protocol. Three 
patients in the control group who received olaparib outside of the trial were not included in the safety analysis set.
§  The anemia category includes anemia, decreased hemoglobin level, decreased red-cell count, decreased hematocrit level, erythropenia, 
macrocytic anemia, normochromic anemia, normochromic normocytic anemia, and normocytic anemia. Among the patients in the overall 
population, anemia was reported in 49% and a decreased hemoglobin level in less than 1%. Among the patients who crossed over to re-
ceive olaparib, anemia was reported in 49%, a decreased hemoglobin level in 1%, decreased red-cell count in 1%, and macrocytic anemia  
in 1%.
¶  Fatigue or asthenia is a grouped term that includes fatigue, asthenia, or both.
‖  The most common serious adverse events, regardless of the investigators’ assessment of causality, are listed in Table S7 in the 
Supplementary Appendix.
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